Sanofi (ADR) (NYSE:SNY)

CAPS Rating: 4 out of 5

A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.

Recs

1
Player Avatar anton123 (< 20) Submitted: 6/25/2009 10:37:06 AM : Underperform Start Price: $26.81 SNY Score: +11.25

UBS’s Amusa has a “sell” rating on Sanofi and has a “buy” rating on Novo Nordisk A/S, which produces a rival diabetes treatment called Levemir.

“We have to be careful not to taint a medicine which helps many patients, but if Sanofi have data we should see it,” said Kevin Scotcher, an analyst at Liberum Capital Ltd. in London. Sanofi’s Origin study, which is investigating the cardiovascular safety of Lantus, is likely to be completed in 2012, Bessaud said.

Featured Broker Partners


Advertisement